GC5107

BIOLOGICAL2 trials

Sponsors

Green Cross Corporation, GC Biopharma Corp

Conditions

Immunologic Deficiency SyndromesPrimary Immune Deficiency

Phase 3

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

CompletedNCT02783482

Green Cross CorporationImmunologic Deficiency Syndromes

Start: 2016-10-31End: 2019-07-31Updated: 2022-12-09

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Active, not recruitingNCT04565015

GC Biopharma CorpPrimary Immune Deficiency

Start: 2020-12-21End: 2026-11-30Target: 24Updated: 2025-07-25

Related Papers

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Frontiers in Immunology2021-07-084 citations